Mitochondria-Targeted Compounds - SPARC

More documents

Recommendations

Info

Annu Rev Pharm Tox (2007) 47 629-656
Potency of MitoQ in a Friedreich‘s Ataxia model120100MitoQMitoQ + FCCPDecylubiquinoneIdebenone8060402000.0001 0.001 0.01 0.1 1 10 100 1000 10000 100000Concentration [nM]FASEB J (2003) 17 1974-1978
Page 1 and 2: Targeting Antioxidants and RedoxPro
Page 3 and 4: Mitochondria and Oxidative StressOv
Page 10 and 11: Critical questions•ROS-Which?-Whe
Page 12: Mitochondrial ROS metabolism
Page 15 and 16: JBC (2001) 276 4588-4596Uptake of M
Page 17 and 18: Prevention of Lipid Peroxidation by
Page 19 and 20: MitoQ variantsFEBS Letts (2004) 571
Page 21 and 22: JBC (2005) 280 21295 - 21312
Page 23 and 24: Complex III with MitoQ
Page 25 and 26: Steric inhibition is not involved i
Page 28 and 29: JBC (2007) in press
Page 33 and 34: Distribution of TPMP in Mice25TPMP
Page 35 and 36: Protection of mitochondrial functio
Page 37 and 38: Pharmaceutical development of MitoQ
Page 39: Human Phase II trials with MitoQ(An

Mitochondria-Targeted Compounds - SPARC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?